Fri. 8 Mar 2024, 8:04am ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.220) per share which missed the analyst consensus estimate of $(0.100) by 120 percent. The company reported quarterly sales of $141.562 thousand which beat the analyst consensus estimate of $56.500 thousand by 150.55 percent. This is a 205.88 percent increase over sales of $46.280 thousand the same period last year.